BioCentury | Apr 13, 2015
Clinical News

Antineoplastons: Phase II data

...were reported as reversible grade 3/4 toxicities. Data were published in Cancer and Clinical Oncology. Burzynski...
BioCentury | Jun 1, 2009
Clinical News

Antineoplastons: Phase II data

...g/day IV Atengenal for 7 days followed by 10 g/day oral Astugenal for 1 year. Burzynski Research Institute Inc....
BioCentury | May 18, 2009
Clinical News

Antineoplastons: Phase II data

...Data were presented at the Quadrennial Meeting of the World Federation of Neuro-Oncology in Yokohama. Burzynski Research Institute Inc....
BioCentury | May 11, 2009
Clinical News

Antineoplastons: Final Phase II data

...weeks of treatment with a mean maximum dosage of a 18.1/0.5 g/kg/d combination of Atengenal/Astugenal. Burzynski Research Institute Inc....
BioCentury | Jan 19, 2009
Clinical News

Antineoplastons regulatory update

...inhibit neoplastic cell growth, and has Orphan Drug designation in the U.S. to treat gliomas. Burzynski Research Institute Inc....
BioCentury | Dec 8, 2008
Clinical News

Antineoplaston therapy: Phase II data

...was well tolerated. Data were presented at the Society for Neuro-Oncology meeting in Las Vegas. Burzynski Research Institute Inc....
BioCentury | Dec 8, 2008
Clinical News

Antineoplaston therapy regulatory update

...FDA granted Orphan Drug designation for Burzynski's antineoplaston therapy to treat gliomas. The therapy, which combines...
...synthetic peptides that inhibit neoplastic cell growth, is in Phase II testing for the indication. Burzynski Research Institute Inc....
Items per page:
1 - 7 of 7
BioCentury | Apr 13, 2015
Clinical News

Antineoplastons: Phase II data

...were reported as reversible grade 3/4 toxicities. Data were published in Cancer and Clinical Oncology. Burzynski...
BioCentury | Jun 1, 2009
Clinical News

Antineoplastons: Phase II data

...g/day IV Atengenal for 7 days followed by 10 g/day oral Astugenal for 1 year. Burzynski Research Institute Inc....
BioCentury | May 18, 2009
Clinical News

Antineoplastons: Phase II data

...Data were presented at the Quadrennial Meeting of the World Federation of Neuro-Oncology in Yokohama. Burzynski Research Institute Inc....
BioCentury | May 11, 2009
Clinical News

Antineoplastons: Final Phase II data

...weeks of treatment with a mean maximum dosage of a 18.1/0.5 g/kg/d combination of Atengenal/Astugenal. Burzynski Research Institute Inc....
BioCentury | Jan 19, 2009
Clinical News

Antineoplastons regulatory update

...inhibit neoplastic cell growth, and has Orphan Drug designation in the U.S. to treat gliomas. Burzynski Research Institute Inc....
BioCentury | Dec 8, 2008
Clinical News

Antineoplaston therapy: Phase II data

...was well tolerated. Data were presented at the Society for Neuro-Oncology meeting in Las Vegas. Burzynski Research Institute Inc....
BioCentury | Dec 8, 2008
Clinical News

Antineoplaston therapy regulatory update

...FDA granted Orphan Drug designation for Burzynski's antineoplaston therapy to treat gliomas. The therapy, which combines...
...synthetic peptides that inhibit neoplastic cell growth, is in Phase II testing for the indication. Burzynski Research Institute Inc....
Items per page:
1 - 7 of 7